The senior specialist at Skåne University Hospital, Dr. Eero Lindholm, will present unique results from a clinical study of nerve damage in feet in patients with type 1 diabetes. The study shows that there is a strong correlation between Nerve Conduction Studies (NCS) and Multi Frequency Vibrometry with VibroSense Meter. The results shall be presented on EASD (European Association for the Study of Diabetes) in Barcelona in September 2019, where VibroSense also will participate as an exhibitor.
Dr. Lindholm has been awarded a poster presentation where he will present his study results that show that examinations of nerve conduction in the foot is strongly compliant with examination of vibration sensitivity in the foot sole with the VibroSense Meter which utilise Multi Frequency Vibrometry. Nerve Conduction Studies are "Golden Standard" in diagnosis of Diabetic Peripheral Neuropathy in feet of diabetic patients.
EASD is one of the world's most important conferences for researchers in diabetes. EASD has more than 5,000 members from more than 100 countries. This year's conference takes place at September 16-20 in Barcelona and more than 15,000 delegates from more than 130 countries participate. VibroSense Dynamics will participate also this year as an exhibitor at EASD in hall 2, stand A07.
- Dr. Lindholm's study shows that our measuring instrument provides very similar results as today's "Golden standard" in the diagnosis of nerve damage in feet caused by diabetes. Nerve Conduction Studies is a highly specialized examination that is expensive, time-consuming and which can be perceived as unpleasant. Dr. Lindholm's result means that our instrument VibroSense Meter offers a strong alternative to a specialist examination to primary and specialist care, that is painless and significantly faster and much cheaper than Nerve Conduction Studies, ”says Toni Speidel, CEO of VibroSense Dynamics AB.
Toni Speidel, VD VibroSense Dynamics AB,
Phone: +46 40 88 026 (new switch board number)
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (public) sells and develops efficient systems to support early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. The Company, founded in 2005, has been listed on Spotlight stock market since May 2015.
Our vision is that the VibroSense Meter shall be the golden standard instrument for neurological examinations to assess sensory neuropathy and help to improve life conditions for patients having a risk of getting nerve injuries.